 |
 |

Hydroxyamphetamine Increases Intraocular Pressure in Rabbits
Koji Okada, MD;
Douglas S. Gregory, PhD
Arch Ophthalmol. 2001;119:235-239.
ABSTRACT
 |  |
Objective To determine the effect of norepinephrine (NE) released from endogenous
ocular stores on intraocular pressure (IOP) and aqueous flow in rabbits.
Methods The IOP was measured with a pneumatonometer, the aqueous flow with a
scanning fluorophotometer, and the aqueous NE by methylation with catechol-O-methyltransferase in the presence of S-adenosyl-L-[methyl-3H]methionine.
Results Hydroxyamphetamine increased IOP in a dose-dependent fashion. Surgical
removal of the superior cervical sympathetic ganglion eliminated the increase
in IOP and pupil diameter; preganglionic section of the cervical sympathetic
trunk did not. Hydroxyamphetamine increased the concentration of NE in the
aqueous. Increased IOP was not accompanied by increased aqueous flow and was
eliminated by blockade of 1-adrenergic receptors but not -
or 2-adrenergic receptors.
Conclusions Increased IOP after hydroxyamphetamine application is consistent with
earlier suggestions that the nocturnal circadian increase in IOP in rabbits
is mediated in part by NE released from ocular sympathetic nerves. However,
failure of hydroxyamphetamine to increase aqueous flow and of -adrenergic
blockade to blunt the increase in IOP does not support our suggestion that
the nocturnal increase in IOP results in part from NE stimulation of ciliary
process -adrenergic receptors and increased aqueous flow.
Clinical Relevance In addition to increasing pupil diameter, hydroxyamphetamine increases
IOP.
INTRODUCTION
RABBITS HAVE circadian rhythms of intraocular pressure (IOP) and aqueous
flow; both are increased at night.1-6
There is also a nocturnal increase in the aqueous norepinephrine (NE) concentration,
which is probably also circadian.7-8
This suggests that there is a circadian increase in sympathetic input to the
rabbit eye during the night and that increased sympathetic input may be responsible
for the nocturnal increases in IOP and aqueous flow. This idea is supported
by the observations that the nocturnal increases in IOP and aqueous flow are
partially blunted by superior cervical ganglionectomy (CGX) or preganglionic
section of the cervical sympathetic trunk (decentralization [DX])6, 9-11 and
that the nocturnal increase in aqueous NE is abolished by CGX or DX.7-8 Furthermore, Gallar and Liu12 have shown that low frequency preganglionic stimulation
of the cervical sympathetic trunk increased IOP in rabbits, and Liu et al13 showed that intravenous injection of low doses of
NE (10 and 100 ng) increased IOP. Because of the difficulties associated with
interpreting IOP changes after systemic delivery of drugs, we decided to attempt
to circumvent this problem by studying the effects on IOP and aqueous flow
of hydroxyamphetamine, a drug known to cause reversible release of NE from
sympathetic nerve endings in the anterior segment.14
We reasoned that NE released from sympathetic nerve endings by hydroxyamphetamine
is more likely to act at physiologically relevant targets than is NE applied
topically or delivered systemically. It is known that hydroxyamphetamine increases
pupil diameter in rabbits15 and humans,16 and it is an important clinical tool for diagnosis
of Horner syndrome.17-18 Increased
IOP after topical instillation of hydroxyamphetamine has been previously described19 in patients with open angle glaucoma but is thought
not to compromise the clinical utility of this drug for diagnosis of Horner
syndrome. We report herein that hydroxyamphetamine also increases IOP in rabbits.
SUBJECTS AND METHODS
Rabbits for all studies were used in accordance with the Association
for Research in Vision and Ophthalmology Statement for the Use of Animals
in Ophthalmic and Vision Research. Male New Zealand White rabbits weighing
2 to 2 kg were housed in rooms with lighting schedules of alternating
12-hour periods of light and dark (12L:12D) for at least 2 weeks before being
used.1, 9 Lights on
is defined as 00:00 circadian time (CT), and, therefore, lights off is at 12:00 CT. Unilateral CGX or DX was done and evaluated as previously
described10-11; after surgery,
rabbits were housed in 12L:12D for at least 2 weeks before being used. The
IOP was measured using either a Digilab 30D or Micro One tonometer (Bio-Rad
Ophthalmic Division, Cambridge, Mass) or a 30 Classic pneumatonometer (Mentor
O & O, Inc, Norwell, Mass), previously calibrated in rabbits. Drugs were
dissolved in Hanks balanced salt solution and delivered by unilateral topical
instillation; the same volume of balanced salt solution was instilled in contralateral
eyes. Hydroxyamphetamine was also delivered by intravitreal injection; contralateral
eyes were injected with the same volume of balanced salt solution. A drop
of 0.5% proparacaine hydrochloride (Alcaine; Alcon, Inc, Humacao, Puerto Rico)
diluted to 0.05% with balanced salt solution was applied to each eye immediately
before applanation. The IOP was measured during darkness by the light of a
dim red bulb (Delta 1, Dallas, Tex).1, 9, 20
Pupil diameter was estimated by comparing rabbit pupils with semicircles of
known diameter on a clinical examination card. Drugs were applied topically
to the cornea in a volume of 50 µL. Intravitreal injection was done
as previously described21; 0.5% proparacaine
hydrochloride was applied topically, and then 10 µL of 1% hydroxyamphetamine
was injected through the sclera and into the vitreous with a 50-µL syringe
(Hamilton, Reno, Nev) fitted with a 30-gauge needle. Aqueous flow was measured
by the corneal depot method using a scanning fluorophotometer (Fluorotron
Master; Coherent Medical Division, Palo Alto, Calif) as previously described.22 Fifty microliters of 0.3% hydroxyamphetamine was
applied at 02:00 and 04:00 CT; corneal and anterior chamber fluorescence was
measured every hour for 3 hours beginning at 02:30 CT. Aqueous NE was measured
as previously described8 using catecholamine
assay kits (Amersham Intl, Buckingham, England). Catecholamines in aqueous
samples were converted to [3H]O-methylated derivatives
by treating aliquots of aqueous with catechol-O-methyltransferase
and S-adenosyl-L-[methyl-3H]methionine; the [3H]O-methylated derivatives were separated by thin-layer
chromatography on silica-gel plates (Analtech Inc, Newark, Del); and spots
corresponding to NE were scraped off the plates and counted in a liquid scintillation
counter (RACKBETA, LKB; Wallac, Gaithersburg, Md).
Data are given as mean ± SE.
RESULTS
Topically instilled hydroxyamphetamine increased IOP and pupil diameter
in rabbits; however, the dose dependence of the 2 effects of hydroxyamphetamine
differed. Pupil diameter was increased by 1% hydroxyamphetamine only, whereas
IOP was increased by lower doses as well (Figure 1). Superior cervical ganglionectomy eliminated increased
IOP and pupil diameter after hydroxyamphetamine instillation (Figure 2), but DX did not (Figure
3). Pupil diameter at 01:00 CT (before hydroxyamphetamine treatment)
was 5.1 ± 0.3 and 6.2 ± 0.2 mm in CGX and contralateral eyes
and 5.1 ± 0.2 and 5.7 ± 0.2 mm in DX and contralateral eyes,
respectively. Decentralization slightly increased the response of pupil diameter
to hydroxyamphetamine; the change in pupil dilation in DX eyes was significantly
different from that in contralateral eyes at 02:30, 03:00, and 04:00 CT (P<.05, t test). Decentralization
decreases NE release and thus prejunctional stores of NE may accumulate in
these eyes, resulting in a greater response to hydroxyamphetamine. Intravitreal
injection of hydroxyamphetamine also increased IOP, although the time course
of increased IOP differed from that observed after topical instillation (Figure 4).
|
|
|
|
Figure 1. Hydroxyamphetamine was instilled
topically to one eye at 02:00 circadian time (arrows), and (A) intraocular
pressure and (B) pupil diameter were measured in both eyes (n = 9). Data are
presented as the difference between treated and contralateral eyes.
|
|
|
|
|
|
|
Figure 2. Hydroxyamphetamine (1%) was instilled
topically at 02:00 circadian time (arrows) to both eyes of rabbits that had
previously undergone unilateral sympathectomy (cervical ganglionectomy, n
= 6). Data are expressed as the difference between (A) intraocular pressure
or (B) pupil diameter in eyes on the side of sympathectomy or contralateral
eyes, and intraocular pressure or pupil diameter on a day when the eyes were
not treated with hydroxyamphetamine.
|
|
|
|
|
|
|
Figure 3. Hydroxyamphetamine (1%) was instilled
topically at 02:00 circadian time (arrows) to both eyes of rabbits that had
previously undergone unilateral sympathectomy (decentralization, n = 8). Data
are expressed as the difference between (A) intraocular pressure or (B) pupil
diameter in eyes on the side of sympathectomy or contralateral eyes, and intraocular
pressure or pupil diameter on a day when the eyes were not treated with hydroxyamphetamine.
|
|
|
|
|
|
|
Figure 4. Hydroxyamphetamine (1%, 10 µL)
was injected intravitreally into one eye at 05:00 circadian time (arrow).
Data are compared with the response of the same rabbits to unilateral topical
application of hydroxyamphetamine (1%, 50 µL; n = 6). Data are presented
as the difference between treated and contralateral eyes.
|
|
|
Aqueous NE measured in rabbits killed 30 minutes after unilateral instillation
of 1% hydroxyamphetamine at 03:15 CT was 2.38 ± 0.29 and 0.93 ±
0.20 ng/mL of aqueous from treated and contralateral eyes, respectively (n
= 7; P<.01, t test for
paired data). As previously reported,8 the
concentrations of aqueous epinephrine and dopamine were barely detectable
(below the assay limits) and were not increased by hydroxyamphetamine.
The aqueous flow rate was measured after unilateral topical instillation
of 0.3% hydroxyamphetamine at 02:00 and 04:00 CT; this protocol maintained
elevated IOP for about 3 hours. Aqueous flow from 02:30 to 05:30 CT was 2.79
± 0.14 and 2.86 ± 0.22 µL/min in treated and contralateral
eyes, respectively (n = 8).
Rabbits were treated with adrenergic antagonists 30 minutes before 0.1%
hydroxyamphetamine instillation to determine which adrenergic receptor(s)
mediates the effects of hydroxyamphetamine on IOP. Pretreatment with 1% timolol,
a -adrenergic antagonist, or 0.3% rauwolscine, an 2-adrenergic
antagonist, did not block increased IOP after hydroxyamphetamine instillation;
pretreatment with 0.3% bunazosin, an 1-adrenergic antagonist,
completely eliminated the increase in IOP during the day (Figure 5). These experiments were also done at night. In rabbits,
ocular sympathetic tone, IOP, and the aqueous flow rate are higher at night.1, 7-8 In contrast, epinephrine
secretion from the adrenal medulla and the aqueous flow rate decrease at night
in humans, and timolol reduces the aqueous flow rate only during the day.23-24 Adrenergic antagonists were applied
bilaterally at 13:30 CT and hydroxyamphetamine unilaterally at 14:00 CT. The
same results were obtained with the antagonists at night, although hydroxyamphetamine
increased IOP less at night, when IOP and sympathetic tone are higher. Neither
timolol nor rauwolscine blocked increased IOP after hydroxyamphetamine treatment
(data not shown), but bunazosin eliminated the increase. The difference between
IOP at 30 minutes after unilateral 0.1% hydroxyamphetamine instillation in
treated eyes and that in contralateral eyes in rabbits pretreated with bunazosin
was -1.3 ± 0.7 (n = 6, P = .15), whereas
in the same rabbits on a day when they were not pretreated with bunazosin
the difference was 2.2 ± 0.5 (n = 6; P<.01, t test for paired data). The IOP measured at 04:00 and
13:00 CT in contralateral eyes (before application of hydroxyamphetamine or
adrenergic antagonists) was 18.2 ± 0.1 and 24.1 ± 0.9 mm Hg,
respectively (n = 5). The IOP in these rabbits is at its daily minimum at
about 04:30 CT and its maximum at about 14:30.10
Hydroxyamphetamine did not change pupil diameter in these experiments, nor
did timolol or rauwolscine. Bunazosin decreased pupil diameter at night but
not during the day. Pupil diameter in contralateral eyes (treated with bunazosin
but not with hydroxyamphetamine) relative to pupil diameter in the same eyes
before bunazosin instillation was -1.3 ± 0.2 mm at 14:30 CT,
1 hour after bunazosin instillation (P<.005, t test for paired data).
COMMENT
The increase in IOP after hydroxyamphetamine treatment is mediated by
NE released from ocular sympathetic nerve endings. The effects of CGX and
DX on the IOP response and our observation of increased aqueous NE after topical
application of hydroxyamphetamine are consistent with this. Kronfeld et al19 confirmed by gonioscopy that hydroxyamphetamine did
not increase IOP in their patients by acute angle closure. Angle closure is
also unlikely in our study because pupil diameter was unaffected by hydroxyamphetamine,
except at the highest dose: 1%.
Topical instillation of sympathomimetic agents is known to produce an
initial increase in IOP; the 2-adrenergic agonist brimonidine
has been shown to produce an initial increase in IOP, followed by decreased
IOP.25-26 The initial increase
was eliminated by surgical section of the rectus muscles or by intracameral
infusion of the drug, prompting us to surmise that increased IOP is unrelated
to interaction of brimonidine with intraocular receptor sites or to changes
in aqueous dynamics.25, 27 Intravitreal
injection of hydroxyamphetamine increased IOP; therefore, its effect on IOP
is likely to result from its action at local intraocular sites and reflects
changes of 1 or more parameters of aqueous dynamics.
Sympathetic tone increases at night in rabbits,7-8
and the nocturnal increases in IOP and the aqueous flow rate require sympathetic
input.6-7,9-11
Therefore, we anticipated that hydroxyamphetamine-mediated NE release would
increase IOP and aqueous flow. Because timolol decreased IOP and aqueous flow
in rabbits at night, but not during the day, and did not decrease IOP at night
in sympathectomized rabbits, researchers have argued11, 28
that part of the nocturnal increase in IOP in this species results from NE
stimulation of ciliary process -adrenergic receptors and increased aqueous
flow. The failure of timolol to block increased IOP after hydroxyamphetamine
treatment and our observation of unchanged aqueous flow after hydroxyamphetamine
application do not support this idea. Because stimulation of 2-adrenergic receptors decreases IOP by reducing aqueous flow,29-32 failure
of rauwolscine to block increased IOP after hydroxyamphetamine treatment is
not surprising.
Norepinephrine increases outflow facility in rabbits,33-35
and therefore hydroxyamphetamine-induced NE release would be expected to increase
outflow facility and decrease IOP.
How can we explain the increase in IOP after hydroxyamphetamine treatment?
Bunazosin reduced IOP in rabbits during the day and night, and sympathectomy
eliminated its effect on IOP.22, 36
Decreased IOP after bunazosin instillation was not accompanied by decreased
aqueous flow.22, 37 Bunazosin blocked
the initial increase in IOP after topical application of NE in sympathectomized
rabbits,36 and we show here that bunazosin
eliminated increased IOP after hydroxyamphetamine application. Prazosin hydrochloride,
another 1-adrenergic antagonist, blocked the circadian increase
in IOP observed from 10:00 to 14:00 CT, but had no effect on the increase
in aqueous flow during the same time.38 More
recently, Zhan et al39 have shown that decreased
IOP after topical application of bunazosin in rabbits resulted predominantly
from increased uveoscleral outflow. These observations suggest that hydroxyamphetamine-induced
NE release increased IOP by decreasing uveoscleral outflow. However, the uveoscleral
outflow pathway plays only a minor role in aqueous outflow in the rabbitless
than 10% of the total outflow.40 This makes
it unlikely that a significant increase in IOP could result from decreased
uveoscleral outflow in this species. In summary, hydroxyamphetamine increased
IOP in rabbits by stimulating 1-adrenergic receptors; the
mechanism for increased IOP remains to be identified.
AUTHOR INFORMATION
Accepted for publication August 22, 2000.
This study was supported by grants EY00785 and EY05078 from the National
Institutes of Health, Bethesda, Md; the Connecticut Lions Eye Research Foundation,
Inc, New Haven; and Research to Prevent Blindness, Inc, New York, NY.
The hydroxyamphetamine (1% Paredrine) was from Smith Kline French, Philadelphia,
Pa, or from Leiter's Pharmacy, San Jose, Calif. Timolol maleate was provided
by Merck Sharp & Dohme/Isotopes, West Point, Pa. Rauwolscine hydrochloride
was purchased from Res Biochems Inc, Natick, Mass. Bunazosin hydrochloride
was provided by Santen, Osaka, Japan.
We thank Yoshiaki Kiuchi, MD, and Hiromi Ikeda, MD, who performed the
aqueous flow and norepinephrine measurements, respectively.
Corresponding author and reprints: Douglas S. Gregory, PhD, Department
of Ophthalmology and Visual Science, Yale University School of Medicine, PO
Box 208061, New Haven, CT 06520-8061 (e-mail: douglas.gregory{at}yale.edu).
From the Department of Ophthalmology and Visual Science, Yale University
School of Medicine, New Haven, Conn. Dr Okada is now with the Department of
Ophthalmology, Hiroshima University School of Medicine, Hiroshima, Japan.
The authors have no finanical or proprietary interest in any of the drugs
used in this study or in the companies that have supplied drugs.
REFERENCES
 |  |
1. Rowland JM, Potter DE, Reiter RJ. Circadian rhythm in intraocular pressure: a rabbit model. Curr Eye Res. 1981;1:169-173.
ISI
| PUBMED
2. Rowland JM, Sawyer WS, Tittel J, Ford CJ. Studies on the circadian rhythm of IOP in rabbits: correlation with
aqueous inflow and cAMP content. Curr Eye Res. 1986;5:201-206.
ISI
| PUBMED
3. Smith SD, Gregory DS. A circadian rhythm of aqueous flow underlies the circadian rhythm of
IOP in NZW rabbits. Invest Ophthalmol Vis Sci. 1989;30:775-778.
FREE FULL TEXT
4. McLaren JW, Brubaker RF, FitzSimon JS. Continuous measurement of intraocular pressure in rabbits by telemetry. Invest Ophthalmol Vis Sci. 1996;37:966-975.
FREE FULL TEXT
5. Percicot CL, Schnell CR, Debon C, Hariton C. Continuous intraocular pressure measurement by telemetry in alpha-chymotrypsin-induced
glaucoma model in the rabbit: effects of timolol, dorzolamide, and epinephrine. J Pharmacol Toxicol Methods. 1996;36:223-228.
FULL TEXT
|
ISI
| PUBMED
6. Liu JHK, Gallar J, Loving RT. Endogenous circadian rhythm of basal pupil size in rabbits. Invest Ophthalmol Vis Sci. 1996;37:2345-2349.
FREE FULL TEXT
7. Liu JHK, Dacus AC. Endogenous hormonal changes and circadian elevation of intraocular
pressure. Invest Ophthalmol Vis Sci. 1991;32:496-500.
FREE FULL TEXT
8. Yoshitomi T, Horio B, Gregory DS. Changes in aqueous norepinephrine and cyclic adenosine monophosphate
during the circadian cycle in rabbits. Invest Ophthalmol Vis Sci. 1991;32:1609-1613.
FREE FULL TEXT
9. Gregory DS, Aviado DG, Sears ML. Cervical ganglionectomy alters the circadian rhythm of intraocular
pressure in New Zealand White rabbits. Curr Eye Res. 1985;4:1273-1279.
ISI
| PUBMED
10. Braslow RA, Gregory DS. Adrenergic decentralization modifies the circadian rhythm of intraocular
pressure. Invest Ophthalmol Vis Sci. 1987;28:1730-1732.
FREE FULL TEXT
11. Yoshitomi T, Gregory DS. Ocular adrenergic nerves contribute to control of the circadian rhythm
of aqueous flow in rabbits. Invest Ophthalmol Vis Sci. 1991;32:523-528.
FREE FULL TEXT
12. Gallar J, Liu JHK. Stimulation of the cervical sympathetic nerves increases intraocular
pressure. Invest Ophthalmol Vis Sci. 1993;34:596-605.
FREE FULL TEXT
13. Liu JHK, Dacus AC, Bartels SP. Thyrotropin releasing hormone increases intraocular pressure: mechanism
of action. Invest Ophthalmol Vis Sci. 1989;30:2200-2208.
ABSTRACT
14. Gill JJ, Masson DT, Bartter FC. Effects of hydroxyamphetamine (Paredrine) on the function of the sympathetic
nervous system in normotensive subjects. J Pharmacol Exp Ther. 1967;155:288-295.
FREE FULL TEXT
15. Skarf B, Czarnecki JS. Distinguishing postganglionic from preganglionic lesions: studies in
rabbits with surgically produced Horner's syndrome. Arch Ophthalmol. 1982;100:1319-1322.
FREE FULL TEXT
16. Cremer SA, Thompson HS, Digre KB, Kardon RH. Hydroxyamphetamine mydriasis in normal subjects [see comments]. Am J Ophthalmol. 1990;110:66-70.
ISI
| PUBMED
17. Thompson HS, Mensher JH. Adrenergic mydriasis in Horner's syndrome: hydroxyamphetamine test
for diagnosis of postganglionic defects. Am J Ophthalmol. 1971;72:472-480.
ISI
| PUBMED
18. Cremer SA, Thompson HS, Digre KB, Kardon RH. Hydroxyamphetamine mydriasis in Horner's syndrome [see comments]. Am J Ophthalmol. 1990;110:71-76.
ISI
| PUBMED
19. Kronfeld PC, McGarry HI, Smith HE. The effect of mydriatics upon the intraocular pressure in so-called
primary wide-angle glaucoma. Am J Ophthalmol. 1943;26:245-252.
20. Lee TC, Kiuchi Y, Gregory DS. Light exposure decreases IOP in rabbits during the night. Curr Eye Res. 1995;14:443-448.
ISI
| PUBMED
21. Kiuchi Y, Mockovak ME, Gregory DS. Melatonin does not increase IOP significantly in rabbits. Curr Eye Res. 1993;12:181-190.
ISI
| PUBMED
22. Kiuchi Y, Yoshitomi T, Gregory DS. Do -adrenergic receptors participate in control of the circadian
rhythm of IOP? Invest Ophthalmol Vis Sci. 1992;33:3186-3194.
FREE FULL TEXT
23. Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci. 1984;25:776-778.
FREE FULL TEXT
24. Kacere RD, Dolan JW, Brubaker RF. Intravenous epinephrine stimulates aqueous formation in the human eye. Invest Ophthalmol Vis Sci. 1992;33:2861-2865.
FREE FULL TEXT
25. Burke JA, Potter DE. Ocular effects of a relatively selective 2 agonist (UK-14, 304-18)
in cats, rabbits and monkeys. Curr Eye Res. 1986;5:665-676.
ISI
| PUBMED
26. Burke J, Kharlamb A, Shan T, et al. Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18
(brimonidine) in rabbits and monkeys: a species difference. Ann N Y Acad Sci. 1995;763:78-95.
PUBMED
27. Burke J, Crosson C, Potter D. Can UK-14, 304-18 lower IOP in rabbits by a peripheral mechanism? Curr Eye Res. 1989;8:547-552.
ISI
| PUBMED
28. Gregory DS. Timolol reduces IOP in normal NZW rabbits during the dark only. Invest Ophthalmol Vis Sci. 1990;31:715-721.
FREE FULL TEXT
29. Ogidigben M, Chu T-C, Potter DE. Alpha-2 adrenoceptor mediated changes in aqueous dynamics: effect of
pertussis toxin. Exp Eye Res. 1994;58:729-736.
FULL TEXT
|
ISI
| PUBMED
30. Gabelt BT, Robinson JC, Hubbard WC, et al. Apraclonidine and brimonidine effects on anterior ocular and cardiovascular
physiology in normal and sympathectomized monkeys. Exp Eye Res. 1994;59:633-644.
FULL TEXT
|
ISI
| PUBMED
31. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514-1517.
FREE FULL TEXT
32. Schadlu R, Maus TL, Nau CB, Brubaker RF. Comparison of the efficacy of apraclonidine and brimonidine as aqueous
suppressants in humans. Arch Ophthalmol. 1998;116:1441-1444.
FREE FULL TEXT
33. Sears ML, Sherk TE. Supersensitivity of aqueous outflow resistance in rabbits after sympathetic
denervation. Nature. 1963;197:387-388.
34. Sears ML, Sherk TE. The trabecular effect of noradrenaline in the rabbit eye. Invest Ophthalmol Vis Sci. 1964;3:157-163.
FREE FULL TEXT
35. Eakins KE, Ryan SJ. The action of sympathomimetic amines on the outflow of aqueous humour
from the eye. Br J Pharmacol. 1964;23:374-382.
36. Nishimura K, Kuwayama Y, Matsugi T, Sun N, Shirasawa E. Selective suppression by bunazosin of alpha-adrenergic agonist evoked
elevation of intraocular pressure in sympathectomized rabbit eyes. Invest Ophthalmol Vis Sci. 1993;34:1761-1766.
FREE FULL TEXT
37. Sugiura Y, Araie M. Effects of intraocular pressure change on movement of FITC-dextran
across vitreous-aqueous interface. Jpn J Ophthalmol. 1989;33:441-450.
PUBMED
38. Liu JHK, Dacus AC, Bartels SP. Adrenergic mechanism in circadian elevation of intraocular pressure
in rabbits. Invest Ophthalmol Vis Sci. 1991;32:2178-2183.
FREE FULL TEXT
39. Zhan GL, Toris CB, Camras CB, Wang YL, Yablonski ME. Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral
outflow. J Ocul Pharmacol Ther. 1998;14:217-228.
ISI
| PUBMED
40. Nilsson SF. The uveoscleral outflow routes. Eye. 1997;11:149-154.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|